Metoclopramidhydrochlorid Noridem (Metoclopramide Hydrochloride Monohydrate)

Metoclopramide acts on the dopaminergic pathways that trigger nausea and on gastrointestinal motility, making it useful for several emetic and motility disorders.

• Nausea and vomiting: reduces episodes in acute and chronic settings.
• Post‑operative nausea and vomiting: prevents and treats nausea after surgery.
• Chemotherapy‑induced nausea and vomiting: improves control of emesis associated with cytotoxic drugs.
• Gastroparesis: enhances gastric emptying and relieves related symptoms.
• Gastro‑oesophageal reflux disease (GERD) adjunct: used as an add‑on to improve reflux symptoms when standard therapy is insufficient.

• Metoclopramide exerts its anti‑emetic effect by competitively blocking dopamine D2 receptors in the chemoreceptor trigger zone of the brain, thereby reducing the stimulus for vomiting. In the gastrointestinal tract it antagonizes D2 receptors and stimulates 5‑HT4 receptors, which enhances acetylcholine release and promotes coordinated smooth‑muscle contractions, accelerating gastric emptying and increasing lower‑esophageal sphincter tone.

Metoclopramide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Drowsiness: mild sedation or fatigue.
• Restlessness: feeling of inner tension or agitation.
• Diarrhea: loose stools or increased bowel movements.
• Headache: mild to moderate head pain.
• Extrapyramidal symptoms: transient muscle stiffness or tremor.

Serious or Rare Side Effects

• Tardive dyskinesia: irreversible involuntary movements with long‑term use.
• Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability.
• Severe allergic reaction: rash, itching, swelling, or anaphylaxis.
• Cardiac arrhythmia: irregular heart rhythm, especially with rapid IV administration.
• Hyperprolactinemia: elevated prolactin causing galactorrhea or menstrual disturbances.

When prescribing metoclopramide, clinicians should consider several safety measures to minimize risks.

• Contraindication: avoid in patients with known hypersensitivity to metoclopramide or other dopamine antagonists.
• Extrapyramidal risk: monitor for muscle rigidity, tremor, or dystonia, especially in high‑dose or prolonged therapy.
• Tardive dyskinesia: limit use to the shortest duration necessary to reduce risk of permanent movement disorders.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited.
• Drug interactions: assess concomitant medications that may increase central dopamine blockade or prolong QT interval.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Metoclopramide can alter the activity of several other medicines, requiring careful review of a patient’s medication list.

Major Interactions (Avoid)

• Antipsychotics (e.g., haloperidol, risperidone): additive dopamine blockade may worsen extrapyramidal symptoms.
• MAO inhibitors: combined use can increase risk of hypertensive crisis or serotonin syndrome.
• QT‑prolonging agents (e.g., quinidine, erythromycin): may heighten the potential for cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• CNS depressants (e.g., opioids, benzodiazepines): may enhance sedation and respiratory depression.
• CYP2D6 substrates (e.g., codeine, tramadol): metoclopramide can inhibit metabolism, raising plasma levels.
• Anticholinergic drugs (e.g., atropine): may reduce pro‑kinetic efficacy.